Patents by Inventor Lukas Bammert

Lukas Bammert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INTERLEUKIN-15 BASED IMMUNOCYTOKINES
    Publication number: 20240294594
    Abstract: The present invention inter alia relates to immunocytokines involving IL-15 superagonists (based on IL-15 and the sushi domain of IL-15R?) and an antibody. The invention also provides nucleic acids, vectors, methods and medical uses.
    Type: Application
    Filed: June 23, 2022
    Publication date: September 5, 2024
    Inventors: Irena Adkins, Eva Nedvedová, Guy Luc Michel De Martynoff, Ulrich Moebius, David Béchard, Šárka Pechoucková, Zuzana Antošová, Lenka Kyrych Sadilkova, Roger Renzo Beerli, Lukas Bammert, Lorenz Waldmeier, Iva Valentová, Simona Hošková
  • TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATES
    Publication number: 20240100180
    Abstract: The invention provides an ADC based on an antibody binding to CLDN18.2, wherein the antibody or fragment thereof exhibits increased binding to tumor tissue expressing CLDN18.2 over healthy tissue expressing CLDN18.2.
    Type: Application
    Filed: December 23, 2021
    Publication date: March 28, 2024
    Inventors: Lukas Bammert, Lenka Kyrych Sadilkova, Simona Hoskova, Iva Valentova, Lorenz Waldmeier, Roger Beerli, Ulrich Moebius
  • TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODIES
    Publication number: 20240034783
    Abstract: The invention provides tumor specific anti-CLDN18.2 antibodies or fragments thereof. The antibodies or fragments thereof exhibit increased binding to tumor tissue expressing CLDN 18.2 over healthy tissue expressing CLDN18.2. Further, the antibodies do not exhibit cross-reactivity to CLDN18.1. The invention also provides nucleic acids, vectors, host cells and medical uses.
    Type: Application
    Filed: December 23, 2020
    Publication date: February 1, 2024
    Inventors: Lukas Bammert, Lenka Kyrych Sadilkova, Simona Hoskova, Iva Valentova, Lorenz Waldmeier, Roger Beerli, Ulrich Moebius
  • HUMANIZED CLDN18.2 ANTIBODIES
    Publication number: 20230030674
    Abstract: The invention provides humanized antibodies binding to CLDN18.2 with a high affinity. Further, the antibodies do not exhibit cross-reactivity to CLDN18.1. The invention also provides nucleic acids, vectors, host cells and medical uses.
    Type: Application
    Filed: December 7, 2020
    Publication date: February 2, 2023
    Inventors: Lukas Bammert, Lenka Kyrych Sadilkova, Lorenz Waldmeier, Roger Beerli, Ulrich Moebius